Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653194 | 1.00 | F10 (0.51) | F10DGAT1F2CYP1A2CYP2D6 | |
| SCHEMBL4385803 | 0.92 | F10 (0.50) | F10DGAT1F2 | |
| SCHEMBL1651838 | 0.92 | F10 (0.50) | F10DGAT1F2 | |
| SCHEMBL1651530 | 0.92 | F10 (0.50) | F10DGAT1F2 | |
| SCHEMBL1652827 | 0.92 | F10 (0.55) | F10DGAT1F2CYP1A2CYP2D6 | |
| SCHEMBL4388019 | 0.92 | F10 (0.55) | F10DGAT1F2CYP1A2CYP2D6 | |
| SCHEMBL1385434 | 0.91 | F10 (0.50) | F10DGAT1F2CYP1A2CYP2D6 | |
| SCHEMBL1385435 | 0.91 | F10 (0.50) | F10DGAT1F2CYP1A2CYP2D6 | |
| SCHEMBL4389281 | 0.90 | F10 (0.53) | F10DGAT1F2 | |
| SCHEMBL1652597 | 0.90 | F10 (0.53) | F10DGAT1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | claimed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | F10 12/4885DGAT1 1967/4885F2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.